Collecting and analyzing eye fluid from children with retinoblastoma
Official title: Retinoblastoma Patient Clinical Database and Tissue Repository
Run by Children's Hospital Los Angeles · NCT04959097 · Data updated 2026-11-12
This study is trying to see if collecting eye fluid from children with retinoblastoma can help find important markers for better treatment and understanding of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 0 Years to 18 Years |
| Sex | All |
| Enrollment | 800 (estimated) |
| Sponsor | Children's Hospital Los Angeles Academic / other |
| Locations | 9 sites (Phoenix, Arizona and 8 other locations) |
| Status | Recruiting |
| Started | January 1, 2017 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2030 |
| Registry record updated | April 22, 2026 |
| Trial ID | NCT04959097 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are infants and children up to 18 years old diagnosed with unilateral or bilateral retinoblastoma.
✕Probably not a fit
Patients who are only referred for second opinions and not treated at Children's Hospital Los Angeles will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on retinoblastoma, a primary eye cancer in infants and toddlers, by utilizing aqueous humor as a liquid biopsy to detect tumor-derived markers. The study aims to systematically record clinical data and collect biomaterials such as aqueous humor, blood, and saliva from patients diagnosed with unilateral or bilateral retinoblastoma. By correlating phenotypic and genotypic data, the research seeks to identify clinically relevant biomarkers that could improve prognostication and facilitate personalized treatment plans. This approach addresses the limitations of traditional diagnostic methods that require surgical removal of the eye.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic capabilities and personalized treatment options for children with retinoblastoma.
How similar studies have gone: While the use of aqueous humor as a liquid biopsy is a novel approach in retinoblastoma, similar methodologies in other cancers have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients, age 0 days to 18 years, with a diagnosis unilateral or bilateral retinoblastoma (RB) seen at CHLA (Children's Hospital Los Angeles). Exclusion Criteria: * Patients referred for second opinions only and not treated at CHLA for any reason.
Where it's running
-
Phoenix Children's Hospital
Phoenix, Arizona, United States Recruiting -
Children's Hospital Los Angeles
Los Angeles, California, United States Recruiting -
Emory University Children's Healthcare of ATL
Atlanta, Georgia, United States Recruiting -
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States Recruiting -
Oregon Health & Science University: Casey Eye Institute
Portland, Oregon, United States Recruiting -
Wills Eye Institute
Philadelphia, Pennsylvania, United States Recruiting
Show 3 more locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, United States Recruiting -
Seattle Children's Hospital; University of Washington
Seattle, Washington, United States Recruiting -
The Hospital for Sick Children (Toronto SickKids)
Toronto, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Jesse L Berry, MD — Children's Hospital Los Angeles
- Study coordinator: Jesse L Berry, MD
- Email: jberry@chla.usc.edu
- Phone: 323-361-4510
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Linking RB1 genetic changes to eye tumors and metastasis
We will use targeted long-read genetic sequencing on people with retinoblastoma to see if specific RB1 mutations match tumor features and the risk of spread.
-
High-dose Topotecan treatment for recurrent retinoblastoma with vitreous seeds
This study is testing whether high-dose Topotecan can help patients with recurrent retinoblastoma and vitreous seeds keep their eye while fighting the tumor.
-
Treatment for advanced retinoblastoma using a chemoplaque
This study is testing a new treatment using a special chemotherapy patch for young children with advanced retinoblastoma to see if it helps fight the cancer while keeping their vision safe.
-
New treatment for children with hard-to-treat retinoblastoma
This study is testing a new drug for children with hard-to-treat eye cancer to see if it works better and has fewer side effects than standard chemotherapy.
-
Understanding the incidence and outcomes of trilateral retinoblastoma
This study looks at how common trilateral retinoblastoma is and how well patients survive, comparing data from different countries to see if there are differences based on income levels.
-
Chemotherapy for high-risk retinoblastoma after eye removal
This study is testing if giving chemotherapy after removing the eye can help prevent high-risk retinoblastoma from coming back in children with Stage I disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.